I am a
Home I AM A Search Login

Papers of the Week


Papers: 8 Feb 2020 - 14 Feb 2020


Pharmacology/Drug Development

PAIN TYPE:
Migraine/Headache


2019


Front Pharmacol


10

Efficacy and Safety of Rimegepant for the Acute Treatment of Migraine: Evidence From Randomized Controlled Trials.

Authors

Gao B, Yang Y, Wang Z, Sun Y, Chen Z, Zhu Y, Wang Z
Front Pharmacol. 2019; 10:1577.
PMID: 32038251.

Abstract

As one of the novel therapeutic drugs that targets Calcitonin gene-related peptide (CGRP), 75 mg rimegepant has been used for the acute management of migraine, which is one of the most common neurological diseases worldwide. Several clinical trials have been conducted to investigate the efficacy and safety of rimegepant for the acute management of migraine, but no systematic review of existing literature has been performed. We therefore performed a meta-analysis to investigate the efficacy and safety of rimegepant in treatment of patients with migraine.